Valeritas presents 'positive' findings from its MOTIV4CONTROL study
Valeritas Holdings announced it presented positive findings from its MOTIV4CONTROL study as a poster at The 11th International Conference on Advanced Technologies & Treatments for Diabetes, or ATTD, February 15 to 17, in Vienna, Austria. This retrospective study evaluated the safety and efficacy of a simple physician-driven insulin titration algorithm in adult patients diagnosed with T2D prescribed V-Go. Using four-point self-monitored blood glucose profiles, an algorithm recommended bolus up-or down-titration based on glucose readings. After four months of V-Go use, with insulin dose adjustments occurring predominantly during the first three weeks, an A1C target of 7.5% or lower was achieved in 67% of the study's fifteen participants. A mean significant A1C reduction of 1.6% was also observed with a significant decrease in the mean total daily dose of insulin. Hypoglycemia prevalence decreased from 23% at baseline to 7% of patients by month four. "This study demonstrates that V-Go, combined with a simplified insulin titration algorithm, can reduce A1C levels, insulin usage and the prevalence of hypoglycemia," said John Timberlake, President and CEO of Valeritas. "While we remain focused on growing our customer base in the U.S., we welcome opportunities such as at the ATTD to present our compelling clinical data to European audiences as we explore potential commercial partners to distribute V-Go in the region."